HumacyteHUMA
HUMA
About: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
Employees: 220
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
47% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 38
26% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 31
6.85% more ownership
Funds ownership: 32.72% [Q4 2024] → 39.58% (+6.85%) [Q1 2025]
4% more funds holding
Funds holding: 162 [Q4 2024] → 168 (+6) [Q1 2025]
15% less call options, than puts
Call options by funds: $2.56M | Put options by funds: $3M
51% less capital invested
Capital invested by funds: $213M [Q4 2024] → $104M (-$109M) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
57%
upside
Avg. target
$14.33
464%
upside
High target
$25
884%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert | 884%upside $25 | Buy Maintained | 9 Jul 2025 |
HC Wainwright & Co. Swayampakula Ramakanth | 57%upside $4 | Buy Assumed | 14 May 2025 |
Benchmark Bruce Jackson | 451%upside $14 | Buy Maintained | 14 May 2025 |
Financial journalist opinion
Based on 4 articles about HUMA published over the past 30 days
Neutral
Zacks Investment Research
12 hours ago
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.54, representing a -1.17% change from its previous close.
Neutral
GlobeNewsWire
2 days ago
Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency
DURHAM, N.C., July 08, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency.
Neutral
Zacks Investment Research
1 week ago
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.09, representing a -1.42% change from its previous close.
Positive
Seeking Alpha
4 weeks ago
Humacyte: Revenue Ramp From Symvess Incoming
Humacyte's Symvess offers a significant clinical advance in vascular trauma, with strong efficacy and cost benefits over synthetic grafts and autologous vein grafts. The company targets a $200M-$480M annual revenue opportunity, depending on market penetration and future FDA approvals for expanded indications. Financial risks remain due to high cash burn and potential dilution, but current valuation appears reasonable given future growth prospects and insider buying.
Neutral
GlobeNewsWire
1 month ago
Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting
DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the results from its V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for patients at high risk of autologous arteriovenous fistula (AVF) maturation failure with end-stage renal disease were presented in a plenary session at the Society for Vascular Surgery Vascular Annual Meeting (VAM25), held in New Orleans, LA, on June 6, 2025.
Neutral
GlobeNewsWire
1 month ago
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV™) in arteriovenous access for high-risk patients with end-stage renal disease was accepted for an oral presentation at the Society for Vascular Surgery Vascular Annual Meeting (VAM25).
Positive
Zacks Investment Research
1 month ago
Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Neutral
GlobeNewsWire
1 month ago
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D.
Neutral
Seeking Alpha
1 month ago
Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
Humacyte, Inc. (NASDAQ:HUMA ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Founder, President and Chief Executive Officer Dale Sander - Chief Financial Officer, Chief Corporate Development Officer and Treasurer BJ Scheessele - Chief Commercial Officer Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen Kristen Kluska - Cantor Fitzgerald Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Humacyte's First Quarter Results Conference Call. Currently, all participants are in a listen-only mode.
Negative
Zacks Investment Research
1 month ago
Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.29 per share a year ago.
Charts implemented using Lightweight Charts™